Screener
BridgeBio Pharma BBIO Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| 2029 Notes, net | 741,402 | 740,890 |
| 2027 Notes, net | — | 547,015 |
| Deferred royalty obligations, net (3) | 871,185 | 855,030 |
| Operating lease liabilities, net of current portion | 14,216 | 3,811 |
| Deferred revenue, net of current portion | 11,776 | 13,080 |
| Other long-term liabilities | 229 | 244 |
| Total liabilities | 3,639,856 | 3,012,606 |
| Commitments and contingencies (Note 7) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's operating lease liabilities?
- BridgeBio Pharma (BBIO) reported operating lease liabilities of $14.22M in Q1 2026.
- How has BridgeBio Pharma's operating lease liabilities changed year-over-year?
- BridgeBio Pharma's operating lease liabilities increased by 189.2% year-over-year, from $4.92M to $14.22M.
- What is the long-term trend for BridgeBio Pharma's operating lease liabilities?
- Over 5 years (2020 to 2025), BridgeBio Pharma's operating lease liabilities has grown at a -23.6% compound annual growth rate (CAGR), from $14.68M to $3.81M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.
Ask your AI about BridgeBio Pharma's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude